Kintara Therapeutics (NASDAQ:KTRA – Get Rating) was downgraded by investment analysts at Dawson James from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Monday, The Fly reports.
Separately, HC Wainwright cut their price objective on shares of Kintara Therapeutics from $6.00 to $3.00 and set a “buy” rating for the company in a report on Thursday, January 20th.
Shares of KTRA stock traded down $0.03 during trading hours on Monday, reaching $0.16. 28,994 shares of the company’s stock were exchanged, compared to its average volume of 1,759,779. The stock’s 50 day moving average is $0.32 and its 200-day moving average is $0.49. The company has a market cap of $8.02 million, a price-to-earnings ratio of -0.27 and a beta of 1.69. Kintara Therapeutics has a fifty-two week low of $0.14 and a fifty-two week high of $2.85.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Advisor Group Holdings Inc. increased its stake in Kintara Therapeutics by 182.7% in the first quarter. Advisor Group Holdings Inc. now owns 73,367 shares of the company’s stock valued at $130,000 after purchasing an additional 47,415 shares during the period. Virtu Financial LLC increased its stake in shares of Kintara Therapeutics by 371.4% during the fourth quarter. Virtu Financial LLC now owns 64,913 shares of the company’s stock worth $33,000 after acquiring an additional 51,144 shares during the period. Citadel Advisors LLC acquired a new position in shares of Kintara Therapeutics during the fourth quarter worth about $127,000. Geode Capital Management LLC increased its stake in shares of Kintara Therapeutics by 77.3% during the fourth quarter. Geode Capital Management LLC now owns 517,966 shares of the company’s stock worth $264,000 after acquiring an additional 225,902 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Kintara Therapeutics during the fourth quarter worth about $104,000. Institutional investors own 10.37% of the company’s stock.
Kintara Therapeutics Company Profile (Get Rating)
Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer.
- Get a free copy of the StockNews.com research report on Kintara Therapeutics (KTRA)
- Recession Fears Mount After Weak Manufacturing Data
- WD-40 Stock is Ready to Coil like a Piston
- CarMax Stock is Poised to Bounce
- F5 Inc Is a Troubled Stock With Upside Potential
- Why Investors Suddenly Love These 2 Software Stocks
Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.